Loading live market data…

Ainos, Inc.

NASDAQ:AIMD

$1.9 USD

$0 (0.0%)

Volume
48.36K
Average Volume
367.44K
Market Capitalization
$8.6M
P/E Ratio
-0.66
Dividend Yield
0.00%
Price Target
$
Year High
$4.50
Year Low
$1.26
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$0.55

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Chun-Hsien Tsai
Industry Biotechnology
Sector Technology
Current Symbol AIMD
CUSIP 00902F402
CIK 0001014763
Web https://ainos.com
Phone 858 869 2986
Currency USD
Employees 41
Country US

Liquidity

Debt-to-Equity Ratio 2.43
Payout Ratio 0.00
Current Ratio 0.55
Quick Ratio 0.50
Cash Ratio 0.45

Sales & Book Value

Annual Sales $124.16K
Price / Sales 475.00
Cash Flow -0.73
Price / Cash Flow -1.96
Price / Book 2.01

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-3.46
Trailing P/E Ratio -0.66
PEG Ratio -0.01
P/E Growth -0.01
Net Income $-14.77M
Net Margin -76996.25%
Pretax Margin -76991.83%
Return on Equity -160.55%
Return on Assets -63.15%

Financials Score

AltmanZ Score -6.25
Piotroski Score 2.00
Working Capital -2.83M
Total Assets 22.08M
Ebit -13.24M
Market Cap 8.6M
Total Liabilities 16.39M

Poll Results

About Ainos, Inc. (NASDAQ:AIMD) Stock

Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, Cali ... fornia-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.

VASRO Research Highlights Ainos' Expansion of Smell AI Into Patient-Level Breath Intelligence

2026-06-22 09:00:00

HOUSTON, TX / ACCESS Newswire / June 22, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today highlighted a new update report published by VASRO GmbH ("VASRO") reviewing Ainos' planned expansion of its AI Nose platform into patient-level breath intelligence. The VASRO update reviews Ainos' recently announced one-year research program with National Taiwan University, scheduled to begin on July 1, 2026, to evaluate whether AI-analyzed breath patterns may help distinguish acute exacerbations of chronic obstructive pulmonary disease ("COPD") from acute decompensated heart failure among patients presenting with shortness of breath.

Ainos Expands Smell AI Platform into Digital Breath Intelligence Through National Taiwan University Research Program

2026-06-17 08:00:00

Program expands Ainos' Smell AI platform from environmental intelligence into digital breath intelligence for emergency medicine research HOUSTON, TX / ACCESS Newswire / June 17, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization and Smell AI technologies, today announced a new research program with National Taiwan University ("NTU") to explore the use of Smell AI in emergency medicine. The program, titled "Rapid Diagnosis of Dyspneic Patients in the Emergency Department via AI-powered Electronic Nose Technology," will explore the use of Ainos' Smell AI platform to analyze volatile organic compounds ("VOCs") in exhaled breath.

Ainos Releases 2026 Mid-Year CEO Letter to Shareholders

2026-06-08 08:00:00

Building the Olfactory Layer of Physical AI Highlighting Progress Across Semiconductor Manufacturing, Healthcare Infrastructure and Physical AI Applications HOUSTON, TX / ACCESS Newswire / June 8, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization and Smell AI technologies, today released its 2026 Mid-Year Letter to Shareholders from Chairman, President and Chief Executive Officer Eddy Tsai. 2026 First Half Highlights Commercial Momentum Reported 499% year-over-year revenue growth during fiscal year 2025.

VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations

2026-06-05 08:00:00

HOUSTON, TX / ACCESS Newswire / June 5, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today highlighted a recent report published by VASRO GmbH ("VASRO"), discussing the expansion of the Company's AI Nose platform into emergency department operations and the continued growth of its Smell ID data across diverse real-world environments. In the report, VASRO reviews Ainos' recently announced research program at one of Asia's leading academic medical centers, where AI Nose is being deployed within a live emergency department environment to evaluate environmental scent analysis for emergency department overcrowding early warning and respiratory infection risk analysis.

Zacks SCR Discusses Ainos' Expansion of Smell AI into Healthcare Infrastructure Through NTUH Study

2026-06-03 08:00:00

HOUSTON, TX / ACCESS Newswire / June 3, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today announced that Zacks Small-Cap Research ("Zacks SCR") has published a new article discussing Ainos' recently announced healthcare infrastructure study at National Taiwan University Hospital ("NTUH"). The article reviews Ainos' initiative to deploy AI Nose in a live emergency department environment and explores the potential role of Smell AI in environmental monitoring, healthcare infrastructure, and artificial intelligence applications.

Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis

2026-06-01 08:00:00

AI Nose Expands from Semiconductor Facilities into Frontline Healthcare Infrastructure HOUSTON, TX / ACCESS Newswire / June 1, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today announced the launch of a research program at National Taiwan University Hospital ("NTUH"), one of Asia's leading academic medical centers, to deploy AI Nose inside a live emergency department environment for intelligent environmental monitoring, ER overcrowding early warning, and respiratory infection risk analysis. The program aims to expand Smell AI, powered by AI Nose, inside a real-world emergency department environment and expands market opportunities beyond semiconductor and industrial environments into frontline healthcare infrastructure.

VASRO Research Highlights Ainos AI Nose Commercialization Progress and Semiconductor Industry Shift Toward AI-Driven Environmental Intelligence

2026-05-20 08:00:00

HOUSTON, TX / ACCESS Newswire / May 20, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today highlighted a new research update published by VASRO GmbH discussing AI Nose, the Company's AI-powered scent digitization and Smell AI platform, and ongoing commercialization progress across semiconductor manufacturing, robotics integration, and healthcare infrastructure markets. The report notes that the Company is advancing initiatives intended to support potential second half 2026 revenue generation.

Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets

2026-05-13 16:30:00

HOUSTON, TX / ACCESS Newswire / May 13, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced financial results for the first quarter ended March 31, 2026 and provided a business update on recent execution progress for AI Nose across semiconductors and healthcare infrastructure applications . During the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments while continuing to expand its Smell ID datasets and refine its Smell Language Model ("SLM") through deployment and pilot activities.

Frequently Asked Questions

What is the current Ainos, Inc. (AIMD) stock price?

Ainos, Inc.(NASDAQ:AIMD) stock price is $1.9 in the last trading session. During the trading session, AIMD stock reached the peak price of $4.5 while $1.26 was the lowest point it dropped to. The percentage change in AIMD stock occurred in the recent session was 0.0% while the dollar amount for the price change in AIMD stock was $0.

AIMD's industry and sector of operation?

The NASDAQ listed AIMD is part of Biotechnology industry that operates in the broader Technology sector.

Who are the executives of AIMD?

Chih-Heng Lu | Director of Corporate Developoment
Chun-Hsien Tsai | Chief Executive Officer, President & Chairman of the Board
Hsin-Liang Lee | Chief Financial Officer
|
|

How many employees does AIMD have?

Number of AIMD employees currently stands at 41. AIMD operates from 8880 Rio San Diego Drive, San Diego, CA 92108, US.

Link for AIMD official website?

Official Website of AIMD is: https://ainos.com

How do I contact AIMD?

AIMD could be contacted at phone #858 869 2986 and can also be accessed through its website. AIMD operates from 8880 Rio San Diego Drive, San Diego, CA 92108, US.

How many shares of AIMD are traded daily?

The average number of AIMD shares traded daily for last 3 months was 367.44K.

What is the market cap of AIMD currently?

The market value of AIMD currently stands at $8.6M with its latest stock price at $1.9